Final Analysis of the Randomized Phase 3 ESCORT-1st Trial: Camrelizumab Plus Chemotherapy As First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要